---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-22-000030"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:55:41.874544+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q1 net loss $64.3M ($1.27/sh); cash $344.8M; roflumilast PDUFA July 29

## Summary
- Net loss widened to $64.3M ($1.27 per share) from $36.0M ($0.76) in Q1 2021.
- Cash & securities $344.8M at Mar 31, down from $388.6M at Dec 31 2021; ATM added $14.5M.
- PDUFA action date July 29, 2022 for roflumilast cream in plaque psoriasis; commercial prep underway.
- Completed enrollment of pivotal Phase 3 trials for roflumilast foam in seborrheic dermatitis and scalp/body psoriasis.
- R&D spend $40.6M vs $21.6M; G&A $22.0M vs $14.5M, driven by clinical and launch preparations.

## SEC filing metadata
- accession: 0001787306-22-000030
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730622000030/0001787306-22-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730622000030/arqt-20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-22-000030
- JSON: https://secwatch.observer/filing/0001787306-22-000030.json
- Plain text: https://secwatch.observer/filing/0001787306-22-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.